SOURCE: Novo Nordisk A/S

June 22, 2010 05:10 ET

Novo Nordisk re-initiates phase 3 development of liraglutide for obesity

BAGSVAERD, DENMARK--(Marketwire - June 22, 2010) - Novo Nordisk today announced the decision to re-initiate the global phase 3 development programme of liraglutide for the treatment of obesity.


Company Announcement no 32 2010:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

All reproduction for further distribution is prohibited.

Source: Novo Nordisk A/S via Thomson Reuters ONE

Contact Information